Scientists in academic centres and companies around the world desperately search for novel therapeutics and vaccines to treat and prevent COVID-19. However, with lockdowns and limited access to laboratories, researchers are being forced to work from home, putting research continuity at risk. To help scientists continue their R&D,… Read More
22 June 2020 SLAS Transformed is an interactive event focused on omics, synthetic biology and genome editing along with applicable implications for the current pandemic. The two-day event runs from 23-24 June 2020, offering 30-minute scientific research presentations, live exhibitor presentations and one-on-one networking sessions. It will span multiple… Read More
09 June, 2020 The specialist developer and manufacturer of proteins for stem cell, organoid and regenerative medicine applications announced the successful closure of a £1.5 million (US$1.9 million) series A investment round to accelerate the global scale-up of its commercial operations. According to Cambridge based Qkine, the funding… Read More
Collaborative Drug Discovery (CDD), owner of the CDD Vault, a comprehensive drug discovery informatics platform for research laboratories, has asked researchers what they think biotechnology world will look like after Covid-19. A few responses are listed below. “Covid-19 may be the tipping point that shifts us from the… Read More
The CRISPR revolution arrives in immuno-oncology By Helen Stewart-Miller and Thomas Hope Volume 21 Issue 2 - Spring 2020 CRISPR-cas9 technology is having an exciting impact on drug discovery as a whole, but more specifically CRISPR presents enormous opportunities in targeted screening for immuno-oncology research. Clustered regularly-interspaced short palindromic repeats… Read More
Meeting analytical challenges in a brave new world of next generation biotherapeutics By Mani Krishnan and Susan Darling Volume 21 Issue 2 - Spring 2020 The need for innovative advanced analytical tools to accelerate the development of immunotherapies and other complex biologics that may one day cure genetic diseases and… Read More
By Andrii Lozoniuk Volume 21 Issue 2 - Spring 2020 Gathering compound solubility data is a key step during drug discovery that helps ensure cost-effective screening, yet it is a long process and is often underestimated in terms of difficulty. Global sharing of such data can help pharmaceutical companies minimise… Read More
Target discovery and drug development what comes after CRISPR? By Benedict CS Cross Volume 21 Issue 2 - Spring 2020 For an area of research as important and impactful as drug discovery, it is surprising how often efforts in this field are directed by short-term trends. We have seen an… Read More
Reprogramming the stem cell for a new generation of cures By Dr Alex Davenport, Dr Tonya Frolov and Dr Mark Kotter Volume 21 Issue 2 - Spring 2020 The development of new and effective treatments with the potential to cure, or at the very least ease patient suffering, has been… Read More
Drug development 2.0 - The partnership model in practice By Dr Brian Sheehan and Marco Cerato Over the last decade there has been a fundamental shift in the way in which drugs are developed and brought to market. Some years ago, the industry started to see profits falling as research… Read More
Harnessing the modified proteome for increased diagnostic power By Dr David Bramwell, Dr Steven Laval and Dr Jane McLeod Relevant biomarkers are vitally important in personalised medicine, guiding patient matching to specific therapies for earlier, easier and more effective disease identification and treatment. Here we trace the expectations of ’omicsbased… Read More
By Dr Steve Arlington and John Wise As part of its mission to help members anticipate and prepare for changes in the pharmaceutical industry, The Pistoia Alliance has developed a research paper which sets out to consider what the life science, biopharma R&D and healthcare ecosystem might look like in… Read More
Evolution of User Experience for life sciences By Jacek Ziemski, Simon Fortenbacher, James Hoeksma, Jan Taubert, Roger Attrill, Paula de Matos, Andre Richter and Julie Morrison Since 2017 we have seen the slow and steady adoption of User Experience (UX) within the life sciences. User Experience is an evidence-based design… Read More
Using Live-Cell Imaging Systems to Transform Perspectives in Drug Discovery By Helen Stewart-Miller and Dr Kate Tointon Live-cell imaging has transformed the study of cell behaviour and function. The technique allows researchers to monitor internal cell structures, interactions and processes in real-time, and over time. In drug discovery, understanding the… Read More
Unlocking Clinical Trial Data to Uncover New Therapeutic Opportunities By David Wang, Masha Hoffey and Dr Simone Sharma This article discusses opportunities, challenges and best practices in leveraging infrastructure excellence and AI to unlock the value of early or inconclusive clinical trial data. The goal... driving stronger biomarker-based insights and… Read More
How Artificial Intelligence is Transforming Drug Design By Dr Mark Roberts and Dr Sam Genway AI could create a streamlined, automated approach to drug discovery, trawling vast datasets to identify targets, find candidate molecules and predict synthesis routes. Getting there will require significant vision, but we are already seeing exciting… Read More